Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter March 11, 2017

Arsenic and breast cancer: a systematic review of epidemiologic studies

Narges Khanjani, Abu-Bakr Jafarnejad and Leila Tavakkoli

Abstract

Introduction:

Arsenic is one of the heavy metals known to be a cause of cancer and many other serious human health problems. The International Agency for Research on Cancer (IARC), has classified arsenic as a Group 1 carcinogen. Studies were performed in different populations to investigate the association between arsenic and breast cancer and the present paper attempts to review these studies.

Methods and materials:

Accessible electronic resources including, PubMed, Web of Knowledge, Science Direct and Scopus and Google Scholar were searched, with relevant phrases up to October 30, 2016. All articles were reviewed by two people separately and among them, original epidemiologic studies that investigated the association between breast cancer and exposure to arsenic were included.

Results:

Eventually seven articles were selected from 126 retrieved articles. Although three studies (one case-control and two ecological) were not able to show a significant affect, others provide some evidence of a relation between arsenic and breast cancer in specific subgroups.

Conclusion:

Exposure to arsenic may increase the risk of breast cancer. The strength of this relation can vary due to regional and individual differences.

Author Statement

  1. Research funding: Authors state no funding involved. Conflict of interest: Authors state no conflict of interest. Informed consent: Informed consent is not applicable. Ethical approval: The conducted research is not related to either human or animals use.

Appendix

Appendix 1:

Quality assessment for case-control studies based on the Newcastle-Ottawa scale.a

Selection
1Is the case definition adequate?
AYes, with independent validationa
BYes, e.g. record linkage or based on self reports
CNo description
2Representativeness of the cases
AConsecutive or obviously representative series of casesa
BPotential for selection biases or not stated
3Selection of controls
ACommunity controlsa
BHospital controls
CNo description
4Definition of controls
ANo history of disease (endpoint)a
BNo description of source
Comparability
1Comparability of cases and controls on the basis of the design or analysis
AStudy controls for _______________ (Select the most important factor.)a
BStudy controls for any additional factora (This criteria could be modified to indicate specific control for a second important factor.)
Exposure
1Ascertainment of exposure
ASecure record (e.g. surgical records)a
BStructured interview where blind to case/control statusa
CInterview not blinded to case/control status
DWritten self report or medical record only
ENo description
2Same method of ascertainment for cases and controls
AYesa
BNo
3Non-response rate
ASame rate for both groupsa
BNon respondents described
CRate different and no designation

  1. aA study can be awarded a maximum of one star for each numbered item within the Selection and Exposure categories. A maximum of two stars can be given for Comparability.

Appendix 2:

Quality assessment of the case-control studies included in this paper according to the Newcastle Ottawa Assessment scale for case-control studies.

Author, publication yearSelectionComparabilityExposure
Garland et al. (13)*-******-
Muszyńska et al. (11) (conference abstract)*---*-**-
López-Carrillo et al. (10)*****-***
Pineda-Belmontes et al. (12)*-***--*-

  1. *For selection, comparability and exposure, 4, 2 and 3 questions are asked, respectively. Each study has been awarded stars according to the listed items.

References

1. AmericanCancerSociety. Arsenic Last Revised: 07/18/2014 [cited 2016 April 22]. Available from: http://www.cancer.org/cancer/cancercauses/othercarcinogens/intheworkplace/arsenic.Search in Google Scholar

2. US.FoodandDrugAdministration. Metals>Arsenic: FDA; [cited 2016 April 22th]. Available from: http://www.fda.gov/Food/FoodborneIllnessContaminants/Metals/ucm280202.htm.Search in Google Scholar

3. WorldHealthOrganization. Arsenic: WHO; 2012 [cited 2016 April 22]. Available from: http://www.who.int/mediacentre/factsheets/fs372/en/.Search in Google Scholar

4. Oussama M, Kh MA. Guidelines for the early detection and screening of breast cancer. World Health Organization, 2006:24–6.Search in Google Scholar

5. International-Agency-for-Research-on-Cancer(IARC). GLOBAL 2012: Estimated Cancer Incidence, Mortality and prevalence Worldwide in 2012 (Fact Sheet By Population): World Health Organization, 2012 [cited 2016 Nov 6]. Available from: http://globocan.iarc.fr/Pages/fact_sheets_population.aspx.Search in Google Scholar

6. Straif K, Benbrahim-Tallaa L, Baan R, Grosse Y, Secretan B, et al. A review of human carcinogens–part C: metals, arsenic, dusts, and fibres. Lancet Oncol 2009;10(5):453–4.10.1016/S1470-2045(09)70134-2Search in Google Scholar

7. Hinwood AL, Jolley DJ, Sim MR. Cancer incidence and high environmental arsenic concentrations in rural populations: results of an ecological study. Int J Environ Health Res 1999;9(2):131–41.10.1080/09603129973272Search in Google Scholar

8. Baastrup R, Sørensen M, Balstrøm T, Frederiksen K, Larsen CL, et al. Arsenic in drinking-water and risk for cancer in Denmark. Environ Health Perspect 2008;116(2):231.10.1289/ehp.10623Search in Google Scholar PubMed PubMed Central

9. Aballay LR, Díaz MdP, Francisca FM, Muñoz SE. Cancer incidence and pattern of arsenic concentration in drinking water wells in Córdoba, Argentina. Int J Environ Health Res 2012;22(3):220–31.10.1080/09603123.2011.628792Search in Google Scholar PubMed

10. López-Carrillo L, Hernández-Ramírez RU, Gandolfi AJ, Ornelas-Aguirre JM, Torres-Sánchez L, et al. Arsenic methylation capacity is associated with breast cancer in northern Mexico. Toxicol Appl Pharm 2014;280(1):53–9.10.1016/j.taap.2014.07.013Search in Google Scholar PubMed

11. Muszyńska M, Jaworska-Bieniek K, Durda K, Sukiennicki G, Gromowski T, et al. Arsenic (As) and breast cancer risk. Hered Cancer Clin Pract 2012;10(4):A8.10.1186/1897-4287-10-S4-A8Search in Google Scholar

12. Pineda-Belmontes CP, Hernández-Ramírez RU, Hernández-Alcaraz C, Cebrián ME, López-Carrillo L. Genetic polymorphisms of PPAR gamma, arsenic methylation capacity and breast cancer risk in Mexican women. Salud Pública México 2016;58(2):220–7.10.21149/spm.v58i2.7791Search in Google Scholar PubMed

13. Garland M, Morris JS, Colditz GA, Stampfer MJ, Spate VL, et al. Toenail trace element levels and breast cancer: a prospective study. Am J Epidemiol 1996;144(7):653–60.10.1093/oxfordjournals.aje.a008977Search in Google Scholar PubMed

14. Eybpoosh S, Khanjani N. Residual concentrations of Arsenic and its health effects in the Iranian population: a systematic review. J Health Dev 2015;4(2):168–80.Search in Google Scholar

15. Ferreccio C, González C, Milosavjlevic V, Marshall G, Sancha AM, et al. Lung cancer and arsenic concentrations in drinking water in Chile. Epidemiology 2000;11(6):673–9.10.1097/00001648-200011000-00010Search in Google Scholar PubMed

16. Chen Y-C, Su H-JJ, Guo Y-LL, Hsueh Y-M, Smith TJ, et al. Arsenic methylation and bladder cancer risk in Taiwan. Cancer Cause Control 2003;14(4):303–10.10.1023/A:1023905900171Search in Google Scholar

17. Yu RC, Hsu K-H, Chen C-J, Froines JR. Arsenic methylation capacity and skin cancer. Cancer Epidem Biomar 2000;9(11):1259–62.Search in Google Scholar

18. Chen Y-C, Guo Y-LL, Su H-JJ, Hsueh Y-M, Smith TJ, et al. Arsenic methylation and skin cancer risk in southwestern Taiwan. J Occup Environ Med 2003;45(3):241–8.10.1097/01.jom.0000058336.05741.e8Search in Google Scholar

19. Smith AH, Hopenhayn-Rich C, Bates MN, Goeden HM, Hertz-Picciotto I, et al. Cancer risks from arsenic in drinking water. Environ Health Perspect 1992;97:259.10.1016/B978-008043648-7/50022-4Search in Google Scholar

20. Thomas DJ, Styblo M, Lin S. The cellular metabolism and systemic toxicity of arsenic. Toxicol Appl Pharm 2001;176(2):127–44.10.1006/taap.2001.9258Search in Google Scholar

21. Tseng C-H. Arsenic methylation, urinary arsenic metabolites and human diseases: current perspective. J Envir Sci Heal C 2007;25(1):1–22.10.1080/10590500701201695Search in Google Scholar

22. Vahter M. Mechanisms of arsenic biotransformation. Toxicology 2002;181:211–7.10.1016/S0300-483X(02)00285-8Search in Google Scholar

23. Petrick JS, Ayala-Fierro F, Cullen WR, Carter DE, Aposhian HV. Monomethylarsonous acid (MMA III) is more toxic than arsenite in Chang human hepatocytes. Toxicol Appl Pharm 2000;163(2):203–7.10.1006/taap.1999.8872Search in Google Scholar PubMed

24. Steinmaus C, Bates MN, Yuan Y, Kalman D, Atallah R, et al. Arsenic methylation and bladder cancer risk in case-control studies in Argentina and the United States. J Occup Environ Med 2006;48(5):478–88.10.1097/01.jom.0000200982.28276.70Search in Google Scholar PubMed

25. García-Esquinas E, Pollán M, Umans JG, Francesconi KA, Goessler W, et al. Arsenic exposure and cancer mortality in a US-based prospective cohort: the strong heart study. Cancer Epidemiol Biomarkers Prev 2013;22(11):1944–53.10.1158/1055-9965.EPI-13-0234-TSearch in Google Scholar PubMed PubMed Central

26. Smith AH, Marshall G, Yuan Y, Steinmaus C, Liaw J, et al. Rapid reduction in breast cancer mortality with inorganic arsenic in drinking water. EbioMedicine 2014;1(1):58–63.10.1016/j.ebiom.2014.10.005Search in Google Scholar PubMed PubMed Central

Received: 2016-12-13
Accepted: 2017-1-29
Published Online: 2017-3-11
Published in Print: 2017-9-26

©2017 Walter de Gruyter GmbH, Berlin/Boston

Scroll Up Arrow